Lawyers from Gibbs Law Group LLP, along with co-counsel, are serving as Lead Counsel in a proposed securities class action involving NantHealth, Inc. We are pursuing the claims on behalf of Lead Plaintiffs Michael Fontaine and the Southeastern Pennsylvania Transportation Authority, as well as and other purchasers of NantHealth, Inc. (NASDAQ: NH) common stock and securities.
Plaintiffs allege that NantHealth’s founder, Patrick Soon-Shiong, violated federal securities law and artificially inflated stock prices by structuring a purportedly philanthropic donation to the University of Utah such that the University was obligated to pay NantHealth $10 million for research services. Additionally, plaintiffs allege that NantHealth exaggerated the success of one of its key products, called GPS Cancer.
On May 31, 2017, Judge Beverly Reid O’Connell of the United States District Court, Central District of California, appointed Gibbs Law Group LLP and Kehoe Law Firm, P.C. as lead counsel. Judge O’Connell cited the firms’ “significant securities class action litigation experience” and their history of achieving “highly favorable settlements for plaintiffs in previous actions.” Our firms will coordinate and oversee the litigation on behalf of the Plaintiffs.
Plaintiffs filed their Amended Consolidated Class Action Complaint on June 26, 2017. In the coming months, we expect defendants may file a motion seeking to dismiss the case, which we will oppose.
Plaintiffs allege that NantHealth completed its initial public offering of common stock on June 7, 2016, and sold 6,500,000 shares at $14.00 per share.
Plaintiffs also allege that STAT published an article on March 6, 2017 alleging that pursuant to the terms of Soon-Shiong’s donation, the University of Utah was effectively required to spend $10 million on genetics analysis performed by NantHealth, an arrangement which STAT alleges enabled NantHealth to inflate by more than 50 percent the number of test orders it reported to investors in 2016. On this news, the company’s stock price fell $1.67, or 23.29%, to close at $5.50 on March 6, 2017, and closed at $4.55 on March 9, 2017.
Plaintiffs allege that the stock price continued to drop as more information came out about both the donation and the viability of GPS Cancer
Invest in NantHealth (NH)?
If you purchased NantHealth shares in or after the IPO or would like to speak privately with a securities attorney to contribute to or learn more about the investigation, visit our website or contact the securities team directly at (800) 254-9493.
About Girard Gibbs LLP
Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for four consecutive years.